Bluejay Diagnostics (NASDAQ:BJDX) Trading Up 12.7%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was up 12.7% during mid-day trading on Monday . The stock traded as high as $0.65 and last traded at $0.62. Approximately 41,154 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 46,850 shares. The stock had previously closed at $0.55.

Bluejay Diagnostics Stock Performance

The company has a 50 day moving average of $0.76 and a 200 day moving average of $1.90. The stock has a market capitalization of $1.67 million, a price-to-earnings ratio of -0.07 and a beta of 0.85.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.10).

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Sabby Management LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,221 shares of the company’s stock, valued at approximately $92,000. Sabby Management LLC owned about 1.71% of Bluejay Diagnostics as of its most recent filing with the SEC. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.